4.7 Article

Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany

Journal

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Volume 323, Issue 4, Pages 339-351

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2019.21565

Keywords

-

Funding

  1. LifeScience-Stiftung [HMGU 2014.01, HMGU 2016.01]
  2. Juvenile Diabetes Research Foundation International [1-SRA-2014-310-M-R, 3-SRA-2015-72-M-R]
  3. Bavarian State Ministry of Health and Care (Gesund.Leben.Bayern) [LP00228]
  4. LeonaMand Harry B Helmsley Charitable Trust [G-1911-03274]
  5. Deutsche Diabetes-Stiftung [364/11/14]
  6. B. Braun-Stiftung [BBST-D-15-00016]
  7. Deutsche Diabetes Hilfe
  8. Landesverband Bayern der Betriebskrankenkassen
  9. German Federal Ministry of Education and Research
  10. Competence Network Diabetes Mellitus
  11. Federal Ministry of Education and Research [FKZ01GI0805]
  12. German Center for Diabetes Research (DZD e.V.)

Ask authors/readers for more resources

IMPORTANCE Public health screening for type 1 diabetes in its presymptomatic stages may reduce disease severity and burden on a population level. OBJECTIVE To determine the prevalence of presymptomatic type 1 diabetes in children participating in a public health screening program for islet autoantibodies and the risk for progression to clinical diabetes. DESIGN, SETTING, AND PARTICIPANTS Screening for islet autoantibodies was offered to children aged 1.75 to 5.99 years in Bavaria, Germany, between 2015 and 2019 by primary care pediatricians during well-baby visits. Families of children with multiple islet autoantibodies (presymptomatic type 1 diabetes) were invited to participate in a program of diabetes education, metabolic staging, assessment of psychological stress associated with diagnosis, and prospective follow-up for progression to clinical diabetes until July 31, 2019. EXPOSURES Measurement of islet autoantibodies. MAIN OUTCOMES AND MEASURES The primary outcome was presymptomatic type 1 diabetes, defined by 2 or more islet autoantibodies, with categorization into stages 1 (normoglycemia), 2 (dysglycemia), or 3 (clinical) type 1 diabetes. Secondary outcomes were the frequency of diabetic ketoacidosis and parental psychological stress, assessed by the Patient Health Questionnaire-9 (range, 0-27; higher scores indicate worse depression; <= 4 indicates no to minimal depression; >20 indicates severe depression). RESULTS Of 90 632 children screened (median [interquartile range {IQR}] age, 3.1 [2.1-4.2] years; 48.5% girls), 280 (0.31%; 95% CI, 0.27-0.35) had presymptomatic type 1 diabetes, including 196 (0.22%) with stage 1, 17 (0.02%) with stage 2, 26 (0.03%) with stage 3, and 41 who were not staged. After a median (IQR) follow-up of 2.4 (1.0-3.2) years, another 36 children developed stage 3 type 1 diabetes. The 3-year cumulative risk for stage 3 type 1 diabetes in the 280 children with presymptomatic type 1 diabetes was 24.9%([95% CI, 18.5%-30.7%]; 54 cases; annualized rate, 9.0%). Two children had diabetic ketoacidosis. Median (IQR) psychological stress scores were significantly increased at the time of metabolic staging in mothers of children with presymptomatic type 1 diabetes (3 [1-7]) compared with mothers of children without islet autoantibodies (2 [1-4]) (P = .002), but declined after 12 months of follow-up (2 [0-4]) (P < .001). CONCLUSIONS AND RELEVANCE Among children aged 2 to 5 years in Bavaria, Germany, a program of primary care-based screening showed an islet autoantibody prevalence of 0.31%. These findings may inform considerations of population-based screening of children for islet autoantibodies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available